Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$5360.00
-210.00 (-3.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-14.3B · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$144.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-34.6%
↓Gross Margin
36.0%
↓Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+324.5%
FCF CAGR
—
FCF margin
-414.7%
FCF / Net income
0.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.70B · net income $-16.35B · FCF $-15.33B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.70B | $3.70B | $3.36B | $323.9M | $48.4M |
| Net Income | $-16.35B | $-16.35B | $-29.38B | $-12.06B | $-10.56B |
| EBITDA | $-12.73B | $-12.73B | $-23.87B | $-12.97B | $-10.08B |
| EPS | -607.00 | -607.00 | -1248.00 | -532.00 | -474.00 |
| Gross Margin | 36.0% | 36.0% | 8.5% | 24.2% | 100.0% |
| Operating Margin | -420.1% | -420.1% | -561.0% | -5055.6% | -19661.2% |
| Net Margin | -442.0% | -442.0% | -874.1% | -3724.2% | -21849.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.14 | 0.23 | 0.01 |
| Current Ratio | 1.72 | 1.72 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-15.33B | $-15.33B | $-12.40B | $-14.26B | $-8.02B |
| Returns | |||||
| ROE | -34.6% | -34.6% | -54.2% | -19.7% | -20.2% |
| Valuation | |||||
| P/B | 3.06 | 3.06 | 2.89 | 3.15 | 4.49 |
| Growth & Yield | |||||
| Revenue Growth | 10.0% | 10.0% | 937.8% | 569.8% | — |
| EPS Growth | 51.4% | 51.4% | -134.6% | -12.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-25.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-1248.00 → -607.00
Residual
-25.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.